Details of the Drug

General Information of Drug (ID: DMWF5R4)

Drug Name

Melphalan flufenamide

Synonyms

J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[1]
Ovarian cancer	2C73	Phase 1/2	[2]
Plasma cell myeloma	2A83.1	Phase 1/2	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

498.4

Logarithm of the Partition Coefficient (xlogp)

3.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 3143 mgh/L [4]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 432 mcg/L [4]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 4-15 min [4]
Clearance: The clearance of drug is 692 L/h [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.1 minutes (melphalan flufenamide), and 70 minutes (melphalan) [5]
Metabolism: The drug is metabolized to desethyl-melphalan and melphalan [5]
Vd: The volume of distribution (Vd) of drug is 76 L [5]

Chemical Identifiers

Formula: C24H30Cl2FN3O3
IUPAC Name: ethyl (2S)-2-[[(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate
Canonical SMILES: CCOC(=O)[C@H](CC1=CC=C(C=C1)F)NC(=O)[C@H](CC2=CC=C(C=C2)N(CCCl)CCCl)N
InChI: InChI=1S/C24H30Cl2FN3O3/c1-2-33-24(32)22(16-18-3-7-19(27)8-4-18)29-23(31)21(28)15-17-5-9-20(10-6-17)30(13-11-25)14-12-26/h3-10,21-22H,2,11-16,28H2,1H3,(H,29,31)/t21-,22-/m0/s1
InChIKey: YQZNKYXGZSVEHI-VXKWHMMOSA-N

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Binder	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033866)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Wickstrom M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjoberg P, Jerling M, Lehmann F, Richardson P, Anderson K, Chauhan D, Gullbo J: Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017 Jun 8;8(39):66641-66655. doi: 10.18632/oncotarget.18420. eCollection 2017 Sep 12.
5	FDA Approved Drug Products: Pepaxto (Melphalan Flufenamide) Intravenous Injection